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PATIENT	CHARACTERISTICS	ASSOCIATED	WITH	ADHERENCE	
	
OF	PULMONARY	NODULE	GUIDELINES	
	
JONATHAN	M.	IACCARINO	
	
ABSTRACT	
	
Background:	Pulmonary	nodules	are	a	frequent	incidental	finding	on	CT	imaging	and	
present	a	diagnostic	challenge	to	clinicians,	who	must	balance	the	risks	of	under-
evaluation	and	over-evaluation.	Determining	why	patients	have	delayed	or	no	follow-up	
for	incidentally	found	nodules	is	critical	to	optimizing	pulmonary	nodule	outcomes	and	
improving	early	detection	of	potential	lung	malignancy.	
	
Methods:	I	performed	a	retrospective	analysis	of	all	patients	found	to	have	new	
pulmonary	nodules	on	CT	imaging	at	Boston	University	Medical	Center	between	January	
1,	2011	and	June	December	31,	2014.	The	primary	outcome	was	rate	of	pulmonary	
nodule	follow-up	consistent	with	the	2005	Fleischner	Society	Guidelines.	I	assessed	how	
various	patient	demographic	and	clinical	factors	were	associated	with	whether	timely	
follow-up	occurred	in	order	to	identify	potential	characteristics	that	may	contribute	to	
non-guideline	adherent	evaluation.		
	
Results:	Among	3916	patients	found	to	have	a	pulmonary	nodule	during	the	study	
period,	1152	patients	met	study	criteria.	In	the	study	population,	613	patients	(53.2%)	
had	follow-up	consistent	with	the	2005	Fleischner	Society	Guidelines.	In	bivariate	
analysis,	increasing	nodule	size,	white	non-Hispanic	race/ethnicity,	and	a	co-diagnosis	of	
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COPD	were	associated	with	guideline	concordant	follow-up.	In	multivariate	analysis,	
patients	with	nodules	measuring	7–8mm	(OR	1.58,	CI	1.06–2.37)	and	greater	than	8mm	
(OR	1.63,	CI	1.12–2.37)	were	more	likely	to	have	guideline	concordant	follow-up	as	were	
patients	with	a	co-diagnosis	of	COPD	(OR	2.00,	CI	1.45–2.75).	Hispanic	patients	were	
significantly	less	likely	to	have	guideline	concordant	follow-up	(OR	0.59,	CI	0.36–0.97)	
compared	to	white	non-Hispanics	and	uninsured	patients	were	less	likely	to	have	
guideline	concordant	follow-up	(OR	0.56,	CI	0.33–0.96)	than	patients	with	Medicare.	
Similar	patterns	were	noted	in	analysis	of	nodules	at	highest	risk	of	malignancy	
measuring	7mm	or	greater.	
	
Conclusion:	Overall,	the	rate	of	guideline	concordant	pulmonary	nodule	follow-up	
evaluation	was	found	to	be	low.	Guideline	concordant	follow-up	was	significantly	
associated	with	nodule	size	and	presence	of	COPD,	while	delayed	or	absent	follow-up	
was	associated	with	Hispanic	ethnicity	and	lack	of	insurance.	While	these	factors	may	
highlight	potential	targets	for	quality	improvement,	further	research	is	needed	to	better	
understand	the	complexities	in	delivering	guideline	concordant	care	to	patients	in	order	
to	improve	pulmonary	nodule	outcomes	
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INTRODUCTION	
	
Problem	Statement	
Despite	advances	in	diagnostic	methods	and	treatment,	lung	cancer	continues	to	have	a	
high	mortality	rate.	Given	rates	of	cure	and	survival	are	improved	with	early	diagnosis,	
current	strategies	for	reducing	lung	cancer	mortality	are	aimed	at	early	detection	and	
intervention.	Many	lung	cancers	are	detected	at	the	earliest	stage	as	a	pulmonary	
nodule,	a	small	growth	in	the	lung	seen	on	imaging	measuring	less	than	3cm.	
Appropriate	diagnosis	and	evaluation	of	pulmonary	nodules	to	identify	the	subset	that	
are	malignant	is	essential	to	improving	lung	cancer	outcomes.	However,	pulmonary	
nodules	present	a	diagnostic	dilemma	for	clinicians.	Of	the	millions	of	nodules	
diagnosed	yearly,	the	vast	majority	are	benign	and	would	require	no	further	
intervention.	On	the	other	hand,	the	minority	of	nodules	that	are	malignant	represent	a	
potentially	deadly	diagnosis	for	which	early	intervention	can	be	life-saving.	To	help	
clinicians	efficiently	and	effectively	manage	nodules,	clinical	guidelines	present	a	
strategy	for	evaluation	in	an	attempt	to	minimize	over-evaluation	of	likely	benign	
nodules	and	under-evaluation	of	likely	malignant	nodules.	Currently,	however,	actual	
clinical	practice	strays	widely	from	guideline-recommended	pulmonary	nodule	care,	
increasing	risks	of	patient	harms	from	unnecessary	procedures	as	well	as	missed	
opportunities	for	intervention	of	early	malignancy,	which	may	lead	to	a	delay	in	
diagnosis	and	treatment	of	cancer.	Therefore,	interventions	to	improve	guideline	
concordance	in	the	clinical	setting	need	to	be	identified	in	order	to	optimize	pulmonary	
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nodule	evaluation	and	improve	patient	outcomes.	There	are	multiple	targets	for	
potential	optimization	in	the	pulmonary	nodule	evaluation	process,	occurring	at	the	
patient,	clinician,	and	healthcare	system	levels.	While	contributions	from	each	of	these	
three	areas	may	improve	guideline	concordance,	understanding	potential	patient	
characteristics	that	may	increase	risk	of	being	lost	to	follow-up	is	a	critical	first	step.	This	
study	will	evaluate	patient	characteristics	associated	with	guideline	concordant	
pulmonary	nodule	follow-up	to	determine	if	and	what	disparities	may	exist.	These	
findings	will	be	used	in	a	future	intervention	and	implementation	study	to	try	to	
optimize	pulmonary	nodule	follow-up.		
	
Literature	Review	
Lung	cancer:	The	leading	cause	of	cancer	death	
Lung	cancer	is	the	leading	cause	of	cancer	death	in	both	men	and	women,	accounting	
for	28%	of	cancer	deaths	in	men	and	26%	of	cancer	deaths	in	women.1	While	many	
cancer	types	have	seen	a	significant	improvement	in	5-year	survival	rates	over	the	past	
25	years,	there	has	been	no	change	in	survival	rate	for	lung	cancer	with	5-year	survival	
in	2009	estimated	to	be	14%,	nearly	identical	to	the	estimated	12%	rate	in	1975.1	
Recent	strategies	for	reducing	lung	cancer	mortality	has	been	multi-faceted	with	efforts	
aimed	at	both	reducing	risk	factors	for	lung	cancer	and	early	detection.	Risk	factor	
reduction	has	mainly	been	through	smoking	cessation,	with	significant	decreases	in	
smoking	rates	with	the	advent	of	dedicated	smoking	cessation	programs	and	
		 3	
medications	to	aid	in	the	quitting	process.2–8	Early	detection	has	been	attempted	at	
several	levels:	lung	cancer	screening	with	yearly	low-dose	chest	computed	tomography	
(CT)	scans,9–15	utilization	of	biomarkers	to	determine	patient	risk,16,17	and	optimization	
of	pulmonary	nodule	evaluation.18,19		
	
The	main	theory	behind	early	detection	of	lung	cancer	is	that	survival	can	be	improved	
with	identifying	lung	cancer	at	earlier	and	more	treatable	stages.	This	is	the	main	
support	for	both	lung	cancer	screening	with	yearly	CT	imaging	and	biomarkers	that	
might	risk-stratify	patients	predisposed	to	developing	lung	malignancy.	Early	detection	
has	been	supported	as	a	strategy	for	improving	survival	in	lung	cancer	in	several	studies,	
but	perhaps	most	notably	in	the	National	Lung	Screening	Trial.15	However,	there	are	
potential	problems	that	arise	with	the	strategy	of	early	detection,	namely	the	risk	of	
false	positive	results	and	the	potential	to	identify	and	intervene	upon	disease	that	might	
have	otherwise	never	caused	morbidity	or	mortality	(i.e.	“overdiagnosis”).	This	is	
particularly	of	note	given	the	experience	with	prostate	cancer,	in	which	early	detection	
has	not	lead	to	improved	mortality,	resulting	in	major	changes	in	the	approach	to	
prostate	cancer	screening.20–23	
	
Optimization	of	pulmonary	nodule	management	differs	from	the	other	strategies	of	
early	detection.	While	yearly	low	dose	CT	imaging	and	biomarkers	can	be	used	in	
screening	asymptomatic	patients	for	lung	cancer,	pulmonary	nodule	management	
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occurs	in	patients	already	determined	to	have	an	abnormality.	These	are	patients	found	
to	have	an	incidental	nodule	on	an	imaging	study	that	carries	with	it	a	potential	risk	of	
malignancy.	This	is	in	contrast	to	screening	studies:	while	screening	studies	attempt	to	
identify	patients	with	an	imaging	abnormality,	pulmonary	nodule	management	requires	
evaluation	of	an	abnormality	already	known	to	exist.	However,	false	positives	are	still	
potentially	problematic,	given	the	vast	majority	of	these	nodules	will	be	benign,	and	the	
risk	for	overdiagnoses	remains	an	issue.	
	
Pulmonary	nodules:	the	key	to	early	lung	cancer	detection	
Pulmonary	nodules	are	common	findings	on	routine	imaging	of	the	chest,	such	as	chest	
x-rays	or	CT	scans.	Pulmonary	nodules	have	represented	a	diagnostic	challenge	for	
clinicians	dating	back	to	the	discovery	of	the	x-ray	in	1897.	The	approach	to	evaluation	
and	treatment	of	these	findings	were	controversial	in	the	early	years	of	the	x-ray.	In	
1936,	Graham	and	Singer	argued	for	surgical	removal	of	all	pulmonary	nodules	as	the	
treatment	modality	of	choice.24	Similarly,	Alexander	in	1942	and	Harrington	in	1951	
both	described	thoracotomy	as	the	optimal	method	for	diagnostic	workup	for	a	solitary	
pulmonary	nodule.25,26	However,	over	the	next	decade,	it	was	recognized	that	a	
pulmonary	nodule	could	represent	a	number	of	diseases,	both	malignant	and	benign,	
with	significant	difficulty	differentiating	between	the	potential	diagnoses.27–32	In	1956	
and	1958,	two	different	case	series	on	pulmonary	nodules	attempted	to	identify	
patterns	associated	with	increased	likelihood	of	malignancy.33,34	Their	findings	
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suggested	that	there	were	perhaps	characteristics	of	the	nodule	itself	including	its	rate	
of	growth	that	could	indicate	whether	a	nodule	had	malignant	potential.	The	evaluation	
of	pulmonary	nodules	with	x-ray	alone	remained	a	suboptimal	modality;	although	it	was	
clear	that	surgical	resection	of	all	nodules	was	certainly	unwarranted,	as	the	large	
majority	appeared	to	be	benign.	
	
The	development	of	the	CT	scan	in	the	early	1970s	was	a	major	advance	in	the	
identification,	evaluation,	and	management	of	the	pulmonary	nodule.	Soon	after	CT	
imaging	started	being	utilized	in	clinical	care,	the	increased	sensitivity	for	identification	
of	pulmonary	nodules	was	apparent.35,36	With	an	increased	number	of	nodules	to	
evaluate	and	greater	detail	in	the	modality	of	detection,	researchers	were	better	able	to	
identify	patterns	in	nodule	appearance,	including	size,	shape,	and	calcification	pattern,	
as	well	as	the	rate	of	nodule	growth	associated	with	malignant	vs.	benign	lesions.37–40	
However,	the	challenge	of	determining	which	nodules	warranted	additional	follow-up	
and	which	could	be	observed	remained	and	would	continue	to	be	a	diagnostic	dilemma	
for	clinicians	over	the	next	several	decades.	
	
Since	the	early	development	of	the	CT	scan,	there	have	been	significant	improvements	
in	the	method	and	quality	of	CT	imaging.	This	has	led	to	an	increased	number	of	
identified	nodules	given	an	even	higher	sensitivity	and	the	increased	utilization	of	CT	
imaging	as	a	diagnostic	modality	for	a	variety	of	diseases.	It	is	now	estimated	that	
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pulmonary	nodules	occur	as	an	incidental	finding	in	up	to	39%	of	all	CT	scans	
performed.41,42	This	accounts	for	approximately	1.5	million	nodules	identified	on	a	
yearly	basis.43	Most	of	these	nodules	are	benign	findings,	with	95%	turning	out	to	be	
inflammation,	infection,	scar	tissue,	or	other	non-malignant	disease.	While	only	5%	of	
these	nodules	turn	out	to	be	lung	cancer,	identifying	potential	cancer	at	this	early	stage	
would	be	a	critical	step	in	improving	patient	outcomes	for	lung	cancer.	As	more	nodules	
are	identified,	the	importance	of	being	able	to	distinguish	between	benign	and	early	
malignancy	has	been	only	magnified	and	remains,	perhaps,	one	of	the	keys	to	improving	
lung	cancer	survival	rates.	
	
Guidelines	for	pulmonary	nodule	evaluation	
The	utilization	of	CT	imaging	in	clinical	practice	increased	the	opportunity	to	study	the	
natural	history	of	pulmonary	nodules	and	improved	the	ability	to	accurately	describe	
changes	in	nodule	size	and	character.	Subsequently,	studies	were	undertaken	to	better	
delineate	nodules	that	appeared	benign	compared	to	those	with	malignant	potential.	In	
1997,	Swensen	et	al.	performed	a	retrospective	cohort	study	in	order	to	derive	a	clinical	
prediction	model	to	identify	malignant	nodules.44	In	their	study,	they	determined	
several	nodule	characteristics	(size,	spiculation/shape,	and	location)	that	were	
associated	with	a	higher	risk	of	malignancy.	Similarly,	other	studies	evaluated	the	
association	between	the	rate	of	growth	of	a	nodule	and	its	malignancy	risk.45–49	
Henschke	et	al.	would	take	this	a	step	further	in	1999,	identifying	nodules	with	higher	
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risk	features	based	on	nodule	size	and	characteristics	and	recommending	follow-up	CT	
imaging	at	3,	6,	12,	and	24-month	intervals	for	these	high-risk	nodules.50	While	their	
study	presented	a	potential	strategy	for	nodule	evaluation,	they	recognized	a	high	false	
positive	rate	with	this	approach.	Additional	studies	then	looked	to	examine	small,	lower	
risk	nodules	to	determine	their	optimal	follow-up	interval	and	try	to	limit	the	risk	of	
false	positive	CT	findings.51,52	These	studies	were	able	to	identify	an	approximate	cutoff	
value	of	4mm,	below	which	it	seemed	the	risk	of	malignancy	was	extraordinarily	low	
(<1%)	and	limited,	if	any,	follow-up	was	needed.		
	
Simultaneous	to	these	studies	assessing	malignancy	risk	based	on	nodule	size	and	
characteristics,	other	approaches	attempted	to	identify	high-risk	patients	that	may	
require	closer	follow-up.	It	had	been	known	for	some	time	that	the	risk	for	developing	
lung	cancer	in	smokers	was	significantly	higher	than	in	nonsmokers.	This	was	outlined	in	
the	1982	report	of	the	Surgeon	General	in	which	smokers	had	a	10–15	times	greater	risk	
of	lung	cancer	than	nonsmokers.53	However,	family	history	of	lung	cancer	and	other	
exposures,	such	as	asbestos,	were	newly	identified	risk	factors	that	needed	to	be	
considered.54,55	In	these	higher	risk	patients	(smoking	history,	family	history,	asbestos	
exposure),	the	risk	of	an	incidentally	found	nodule	being	malignant	would	be	higher	
than	their	lower	risk	counterparts	based	on	their	higher	baseline	lung	cancer	risk.	How	
to	best	integrate	these	findings	with	those	focused	on	nodule	characteristics	remained	
unclear.		
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In	response	to	the	difficulty	clinicians	faced	in	their	approach	to	pulmonary	nodule	
evaluation,	medical	societies	sought	to	compile	guidelines	based	on	the	available	
evidence	to	aid	clinicians	in	their	decision-making	process.	One	of	the	first	and	most	
popular	guidelines	was	set	forth	by	the	Fleischner	Society	in	2005.56	These	guidelines	
used	the	findings	of	the	prior	studies	looking	at	nodule	size,	growth	rate,	imaging	
characteristics,	and	patient	risk	factors	to	formulate	recommendations	for	the	optimal	
interval	for	follow-up	imaging.	The	guidelines	were	organized	into	categories	based	on	
patient	risk	(low	or	high	risk)	as	well	as	nodule	size,	with	the	recommended	follow-up	
interval	increasing	with	increased	risk	as	well	as	with	increase	in	nodule	size	(Figure	1).	
Other	societies	would	also	produce	similar	recommendations	for	how	to	best	manage	
pulmonary	nodules,57,58	but	the	Fleischner	Society	guidelines	would	become	one	of	the	
more	commonly	utilized	guidelines	based	in	part	on	their	relative	simplicity.	
Figure	1:	Fleischner	Society	2005	recommendations	for	management	of	pulmonary	
nodules.56	
	
The	algorithm	recommended	by	the	Fleischner	Society,	in	addition	to	other	medical	
societies	producing	guidelines,	was	a	critical	step	forward	in	trying	to	optimize	the	
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management	of	pulmonary	nodules.	However,	there	has	remained	significant	variation	
in	clinical	practice	and	deviations	from	the	recommendations	provided	by	medical	
societies.	Variation	in	clinical	practice	has	been	observed	both	on	a	geographic	level	as	
well	as	at	the	clinician	level	with	variation	noted	among	medical	specialties.	Multiple	
studies	have	assessed	compliance	with	the	Fleischner	Society	guidelines,	in	particular,	
looking	at	how	frequently	patients	receive	the	ideal	follow-up	defined	by	prior	evidence.	
One	such	study	performed	in	a	clinic	dedicated	to	pulmonary	nodule	evaluation	and	
follow-up	found	a	guideline	compliance	rate	of	only	55%.59	Other	studies	involving	
pulmonologists	across	the	country	have	found	similarly	poor	guideline	compliance,	with	
rates	as	low	as	48%	and	some	amount	of	geographic	variation	noted.60,61	Amongst	
radiologists,	who	are	responsible	for	interpreting	CT	scans	and	making	
recommendations	based	on	the	results,	there	is	also	notable	deviation	from	guideline	
recommendations.	One	study	showed	adherence	to	the	Fleischner	Society	guidelines	
among	834	radiologists	to	be	58.8%.62	Another	study	surveying	members	of	the	Society	
of	Thoracic	Radiology	utilizing	clinical	vignettes	found	27%	of	radiologists	made	
recommendations	consistent	with	the	Fleischner	Society	guidelines.63		
	
The	Fleischner	Society	guidelines	are	not	the	only	guidelines	that	have	been	difficult	to	
implement	in	clinical	practice.	A	more	recent	guideline	from	the	American	College	of	
Chest	Physicians	in	2013	outlines	in	more	detail	the	recommended	approach	to	the	
newly	discovered	solitary	pulmonary	nodule.64	However,	a	study	of	community	
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pulmonologists	found	these	guidelines	to	be	poorly	followed	in	clinical	practice,	with	
clinicians	not	appropriately	discriminating	in	their	management	of	low,	intermediate,	
and	high-risk	nodules.65	A	separate	study	found	this	discordance	from	guideline	
recommendations	persisted	even	when	clinicians	accurately	predicted	malignancy	risk.66	
While	there	are	numerous	potential	obstacles	to	implementation	of	pulmonary	nodule	
guidelines,	these	studies	seem	to	suggest	clinicians’	ability	to	perceive	malignancy	risk	
does	not	correlate	with	appropriate	nodule	management	based	upon	guideline	
recommendations.		
	
Clinical	importance	of	pulmonary	nodule	guidelines	
Deviation	from	guideline-recommended	pulmonary	nodule	care	is	an	example	of	the	
challenge	of	inducing	clinicians	to	adopt	and	incorporate	guidelines	in	their	treatment	of	
patients.	When	clinicians	act	in	accordance	with	guideline	recommendations,	patient	
outcomes	are	theoretically	optimized.	In	contrast,	when	clinicians	act	discordant	to	
clinical	guidelines,	there	may	be	significant	risk	of	patient	harm.	With	pulmonary	
nodules,	guideline	discordance	may	occur	in	the	form	of	either	under-evaluation	(less	
aggressive	testing	of	malignant	nodules	than	guidelines	recommend)	or	over-evaluation	
(overaggressive	testing	of	benign	nodules).	Given	the	high	mortality	associated	with	
lung	cancer,	missing	the	opportunity	to	intervene	early	on	a	nodule	that	turns	out	to	be	
cancer	could	be	devastating.	If	a	pulmonary	nodule	were	malignant,	it	more	than	likely	
would	represent	stage	IA	lung	cancer,	a	potentially	curable	stage	with	surgical	resection	
		 11	
that	has	a	5-year	survival	rate	of	60%.67,68	With	every	increase	in	cancer	stage,	5-year	
mortality	declines	by	5–10%	through	stage	IV	cancer	with	a	1%	5-year	survival,1,69	
stressing	the	potential	impact	early	intervention	may	have	on	improving	patient	survival	
and	outcomes.				
	
Over-evaluation	of	pulmonary	nodules	also	presents	potential	patient	harms.	Given	that	
the	large	majority	of	nodules	are	benign,	there	is	a	relatively	higher	likelihood	of	
subjecting	patients	to	unnecessary	interventions.	Performing	unnecessary	follow-up	CT	
scans	increases	a	patient’s	radiation	exposure	and	also	increases	the	risk	of	other	benign	
incidental	findings	that	could	require	additional	workup	and	evaluation.	Additionally,	a	
patient	may	be	subjected	to	medical	procedures	including	biopsies	and	potential	
surgery	that	could	have	significant	clinical	complications	and	morbidity.70,71	There	can	
also	be	notable	mental	health	impact	on	patients,	as	the	diagnosis	of	a	pulmonary	
nodule	has	been	shown	to	cause	increased	anxiety	and	emotional	distress	that	can	last	
for	months	to	years.71–74	Subjecting	a	patient	to	unnecessary	follow-up	testing	may	only	
serve	to	increase	their	anxiety	and	mental	stress	regarding	the	diagnosis.	Over-
evaluation	of	nodules	may	also	have	important	implications	on	healthcare	cost.	With	a	
pulmonary	nodule	evaluation	estimated	to	cost	approximately	$50,000	per	occurrence,	
performing	unnecessary	evaluations	could	lead	to	financial	burden	for	both	the	patient	
and	the	healthcare	system.75		
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The	Fleischner	Society	guidelines	were	based	on	analysis	of	the	available	evidence	and	
balanced	the	risks	of	under-	and	over-evaluation	to	try	to	optimize	patient	outcomes.	
While	the	absence	of	high-quality	evidence	comparing	nodule	evaluation	strategies	
makes	the	“ideal”	pulmonary	nodule	management	unknown,	the	Fleischner	Society	
guidelines	provide	an	algorithm	to	assist	clinicians	in	minimizing	over-	and	under	
evaluation	of	pulmonary	nodules	in	an	attempt	to	optimize	patient	outcomes.	These	
guidelines	have	ultimately	been	widely	accepted	as	the	standard	of	care	for	pulmonary	
nodule	evaluation.		
	
Lung	cancer	screening:	raising	the	stakes	
While	the	Fleischner	Society	guidelines	were	intended	for	aiding	clinicians	in	managing	
incidentally	found	pulmonary	nodules,	recent	recommendations	for	lung	cancer	
screening	have	created	another	use	for	the	guidelines.	In	2013,	the	National	Lung	
Screening	Trial	(NLST)	demonstrated	a	reduction	in	lung	cancer	mortality	by	20%	with	
annual	screening	of	high	risk	patients	with	low	dose	CT	scans	of	the	chest.15	In	their	
study,	they	performed	yearly	CT	scans	in	smokers	between	the	ages	of	55	and	74.	Based	
on	the	Fleischner	Society	guidelines,	any	pulmonary	nodule	that	was	over	4mm	was	
considered	a	positive	screen	and	was	evaluated	with	additional	CT	imaging,	or	PET	scan,	
biopsy,	or	surgical	resection	for	higher	risk	nodules.	However,	the	criteria	used	to	
determine	the	appropriate	type	of	evaluation	and	time	interval	was	not	specified	in	the	
study,	instead	allowing	trial	radiologists	to	develop	their	own	diagnostic	follow-up	
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recommendations.	Given	a	total	false	positive	rate	of	23%	found	in	the	NLST	(and	an	
even	higher	rate	found	in	the	real	world	setting76),	there	is	potential	for	significant	
patient	harm	if	nodules	found	during	screening	are	not	managed	appropriately.	
	
Without	set	criteria	for	managing	nodules	found	during	lung	cancer	screening,	it	is	
unclear	what	approach	will	allow	clinicians	in	the	real	world	to	achieve	the	20%	
reduction	in	lung	cancer	mortality	seen	in	the	NLST.	In	setting	up	lung	cancer	screening	
programs,	guidelines	recommend	and	the	Center	for	Medicare	and	Medicaid	Services	
(CMS)	requires	utilization	of	an	algorithm,	such	as	the	Fleischner	Society	guidelines,	for	
pulmonary	nodule	evaluation.77–79.	With	multiple	societies	including	CMS	now	
recommending	annual	CT	scans	for	lung	cancer	screening,11–14	it	is	expected	that	many	
more	nodules	will	be	found	in	these	higher	risk	individuals.	This	will	only	magnify	the	
need	for	guideline	adherence,	with	the	risks	of	under-	and	over-evaluation	being	raised	
even	further.		
	
Potential	for	disparities	in	pulmonary	nodule	evaluation	
In	order	to	improve	the	low	rates	of	concordance	with	pulmonary	nodule	guidelines,	it	is	
important	to	first	identify	the	reasons	why	some	patients	do	not	receive	guideline-
recommended	care.	It	is	particularly	important	to	identify	whether	disparities	exist	
between	certain	patient	groups.	Prior	literature	about	other	clinical	conditions	has	
documented	poor	guideline	adherence	particularly	in	patients	of	minority	race,	ethnicity,	
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and	socioeconomic	status.	For	instance,	a	study	of	diabetes	care	across	the	United	
States	found	lower	rates	of	adequate	diabetes	and	cholesterol	control	in	blacks	and	
Hispanics	when	compared	to	whites.80	Similarly,	a	study	of	guideline	adherence	in	
asthma	found	patients	without	insurance	were	less	likely	to	have	recommended	chronic	
asthma	care	compared	to	patients	with	public	or	private	insurance.81	Disparities	in	
guideline-recommended	care	has	been	well	documented	in	management	of	many	other	
chronic	diseases,	including	osteoporosis,	human	immunodeficiency	virus,	and	
congestive	heart	failure,	among	many	others.82–84		
	
Disparities	have	also	been	identified	in	preventive	medicine,	where	clinicians	aim	to	
keep	health	patients	from	developing	disease,	and	in	disease	screening	aimed	to	
identify	illness	at	an	early	stage.	A	large	study	evaluating	preventive	medicine	in	
cardiovascular	care	found	lower	rates	of	guideline-recommended	blood	pressure	and	
cholesterol	control	in	minority	groups	compared	to	whites	as	well	as	in	women	
compared	to	men.85	Racial	and	ethnic	disparities	have	also	been	identified	in	diabetes	
screening,	depression	screening	and	diagnosis,	and	hepatitis	B	and	C	screening.86–88	
While	disparities	have	not	been	yet	well	examined	in	pulmonary	nodule	evaluation	itself,	
there	have	been	notable	disparities	in	cancer	screening	and	in	treatment	of	lung	cancer.	
For	instance,	it	has	been	well	documented	that	lung	cancer	mortality	outcomes	are	
worse	in	minority	groups	and	under	and	uninsured	patients,	with	these	groups	
presenting	with	more	advanced	disease	and	receiving	less	frequent	guideline-
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recommended	cancer	treatment	than	white	and	insured	patients,	respectively.89–91	
Studies	have	also	found	that	minority	patients	may	be	less	receptive	to	lung	cancer	
screening	due	to	fatalistic	beliefs,	suggesting	cultural	factors	have	the	potential	to	
impact	lung	cancer	outcomes.92,93			
	
With	disparities	in	many	other	areas	of	preventive,	diagnostic,	and	therapeutic	medical	
management,	it	is	likely	that	similar	disparities	exist	in	the	evaluation	of	incidentally	
found	pulmonary	nodules.	One	method	to	combat	these	disparities	in	care	is	the	
development	and	implementation	of	clinical	guidelines.	Guidelines	aim	to	provide	a	
framework	or	algorithm	for	clinicians	to	follow	and	are	particularly	useful	in	times	of	
clinical	uncertainty.	Given	that	pulmonary	nodule	guidelines	help	to	“level	the	playing	
field”	in	various	clinical	scenarios	by	providing	clarity	in	medical	decision-making,	it	is	
important	to	determine	1)	whether	guidelines	are	being	followed	consistently	and	2)	if	
guideline	adherence	varies	by	patient	characteristics	(race/ethnicity,	insurance	status,	
etc.).	Determining	how	guidelines	are	followed	in	the	real-world	setting	will	inform	
future	studies	in	how	to	best	implement	practice	changes	to	optimize	pulmonary	nodule	
evaluation	and	outcomes.	
	
Conceptual	Model	
Whether	a	patient	receives	guideline-recommended	pulmonary	nodule	evaluation	is	
dependent	upon	a	decision-making	process	rooted	in	a	complex	interrelationship	
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between	patient,	clinician,	and	the	larger	healthcare	system.	This	decision-making	
process	is	ultimately	comprised	of	both	clinician	and	patient	decision-making,	as	well	as	
the	interaction	between	the	two	parties	(Figure	2).	Within	the	decision-making	process,	
multiple	factors	affect	the	decision-making	process	that	occurs	among	and	between	
patient	and	clinician.	Some	of	these	factors	consist	of	the	traditional	clinical	criteria	that	
are	based	upon	scientific	evidence	that	provide	data	on	various	diagnostic	tests,	
treatment	options,	and	natural	history	of	the	disease	of	interest.	Making	a	clinical	
decision	requires,	in	part,	the	weighing	of	the	risks	and	benefits	of	a	proposed	diagnostic	
study	or	intervention,	taking	into	account	the	factors	influencing	these	categories.		
	
Other	factors	that	affect	decision-making	are,	perhaps,	more	complex.	Patient	
characteristics,	consisting	of	demographics	(i.e.	age,	sex,	race,	socioeconomic	status)	
and	less	easily	defined	characteristics	(i.e.	patient	beliefs,	fears,	attitudes,	and	values)	of	
course	affect	patient	decision-making,	but	also	may	influence	how	the	clinician	
perceives	the	patient.94,95	Some	of	these	characteristics	may	have	direct	clinical	
relevance,	while	others	may	be	more	be	subliminal	in	how	they	influence	clinician	
perceptions	of	patients’	health.	Similarly,	clinician	characteristics	are	made	up	of	well-
defined	attributes,	such	as	medical	specialty	or	level	of	training,	but	also	include	factors	
such	as	clinical	experience,	values,	and	attitudes.94,95	These	factors	may	influence	
clinician	decision,	but	also	may	affect	patient	perception	of	their	clinician	and	how	the	
patient	interacts	with	the	clinician	in	the	decision-making	process.	Finally,	there	are	
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features	of	the	practice	setting	that	may	influence	how	clinicians	and	patients	make	
medical	decisions.	Characteristics	such	as	the	type	of	practice,	geographic	location,	
reimbursement	structure,	local	culture	and	practice	patterns,	and	availability	of	
resources	may	be	considerations	for	why	a	patient	does	or	does	not	receive	a	certain	
diagnostic	test	or	therapeutic	intervention.94,95	
	
	
Figure	2:	Medical	and	non-medical	factors	influencing	decision-making	in	pulmonary	
nodule	evaluation	(adapted	from	McKinlay	et	al.,95	Charles	et	al.,96	and	Hajjaj	et	al.94)	
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My	study	on	pulmonary	nodule	evaluation	will	draw	on	this	conceptual	model	(figure	2)	
to	explore	disparities	among	patients	in	guideline	concordant	pulmonary	nodule	
evaluation.	From	this	model,	I	propose	three	likely	potential	explanations	that	could	
account	for	the	variation	seen	in	guideline	concordant	pulmonary	nodule	evaluation:	1)	
Patients	are	unable	or	unwilling	to	undergo	the	follow-up	evaluation	recommended	by	
their	clinician;	2)	Clinicians	are	unable	or	unwilling	to	implement	guideline	
recommendations	in	real	world	practice;	or	3)	There	is	an	insufficient	availability	of	
resources	and	processes	of	care	at	the	healthcare	system	level	to	accommodate	the	
required	follow-up	recommended	in	the	guidelines.	This	study	will	take	the	first	step	in	
exploring	the	first	of	these	explanations	by	evaluating	patient	factors	associated	with	
guideline	adherence	and	nonadherence.	This	will	serve	to	identify	potential	patient-level	
barriers	to	pulmonary	nodule	evaluation.	With	prior	studies	focusing	at	the	clinician	and	
healthcare	system	levels,60,62,63,65,66,97–100	few	studies	have	evaluated	barriers	to	nodule	
guideline	adherence	at	the	patient	level.	Patient	characteristics	may	impact	patient	
knowledge,	attitudes,	and	behavior	related	to	being	able	to	adhere	to	guideline	
recommendations.101–103	Additionally,	patient	characteristics	may	also	influence	
whether	a	clinician	orders	the	appropriate	test	in	the	first	place,	as	factors	such	as	
insurance	status	or	patient	values	may	influence	how	and	when	evaluations	are	
performed.	Predisposing	characteristics,	such	as	age,	marital	status,	race/ethnicity,	
primary	language,	economic	status,	and	education	level	are	all	potential	influences	on	a	
patient’s	perceived	need	for	care	as	well	as	clinician’s	perceptions	of	the	patient’s	need	
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for	care	and	could	affect	whether	a	patient	ultimately	receives	the	recommended	
follow-up.	Determining	which	of	these	factors	are	associated	with	guideline-	concordant	
and	guideline-discordant	pulmonary	nodule	evaluation	will	provide	critical	data	to	
better	understand	medical	decision-making	in	pulmonary	nodule	management.	
	
Summary	
The	main	goal	of	my	study	is	to	determine	which	patient	characteristics	are	associated	
with	pulmonary	nodule	evaluation	guideline	non-adherence.	Identifying	potential	
disparities	in	pulmonary	nodule	evaluation	will	provide	valuable	information	to	better	
understand	which	patients	are	at	greatest	risk	of	being	lost	to	follow-up.	My	study	plans	
to	analyze	the	association	of	patient	factors	such	as	age,	gender,	marital	status,	
race/ethnicity,	primary	language,	economic	status,	and	education	level	with	pulmonary	
nodule	guideline	non-adherence.	I	will	be	evaluating	all	patients	at	Boston	Medical	
Center	who	were	found	to	have	a	pulmonary	nodule	between	2011	and	2014	(end	date	
selected	to	allow	at	least	two	years	of	follow-up	from	the	time	of	diagnosis).	I	will	be	
determining	which	patients	received	appropriate	follow-up	based	on	the	2005	
Fleischner	Society	guidelines.	For	this	study,	I	will	focus	on	pulmonary	nodule	follow-up	
that	is	at	least	as	aggressive	as	recommended	by	the	Fleischner	Society	guidelines.	
While	over-evaluation	certainly	could	lead	to	patient	harm,	there	are	potential	clinical	
reasons	for	a	patient	to	have	follow-up	sooner	than	recommended	that	are	valid	and	
reasonable.	Moreover,	missing	a	cancer,	rather	than	harms	of	overtesting,	is	typically	
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the	greatest	concern	of	patients,	clinicians,	and	healthcare	systems,	thus	making	it	more	
pressing	to	identify	(and	ultimately	to	prevent)	cases	of	under-evaluation	than	over-
evaluation.98,100,104	I	will	be	comparing	the	patient	characteristics	of	these	two	groups	to	
try	to	identify	associations	with	receipt	of	care	that	deviates	from	the	guidelines.	These	
data	will	be	used	to	try	to	predict	which	patients	are	at	highest	risk	of	having	poor	
pulmonary	nodule	follow-up	and	provide	the	basis	for	a	future	study	utilizing	patient	
navigation	for	these	at-risk	groups	to	improve	pulmonary	nodule	outcomes.	This	may	
also	generate	hypotheses	for	potential	intervention	targets	in	other	clinical	settings	on	a	
more	global	level.	
	
Research	Questions	
• What	is	the	rate	of	pulmonary	nodule	follow-up	at	least	as	aggressive	as	
recommended	by	Fleischner	Society	pulmonary	nodule	guidelines	among	the	
patients	at	Boston	Medical	Center?	
Hypothesis:	Less	than	50%	of	patients	at	BMC	will	have	follow-up	evaluation	at	
least	as	aggressive	as	the	Fleischner	guidelines.	
	
• Which	patient	characteristics	are	associated	with	lower	rates	of	guideline-
recommended	pulmonary	nodule	follow-up?	
Hypothesis:	Gender,	marital	status,	economic	status,	and	education	level	will	be	
associated	with	rates	of	guideline-recommended	pulmonary	nodule	follow-up.	
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Male	gender,	single	marital	status,	lower	economic	status,	and	lower	education	
level	will	have	lower	rates	of	guideline	concordant	pulmonary	nodule	follow-up.	
	
Specific	Aims	
Aim	1:	Determine	the	rate	of	concordance	with	the	2005	Fleischner	Society	pulmonary	
nodule	guidelines	(the	accepted	standard	of	care)	at	Boston	Medical	Center.	
	
Aim	2:	Determine	which	patient	characteristics	are	associated	with	lower	rates	of	
guideline	concordant	pulmonary	nodule	follow-up.	
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METHODS	
Data	collection	
Patients	with	new	pulmonary	nodules	between	2011	and	2014	at	Boston	Medical	
Center	(BMC)	were	identified	using	a	database	maintained	by	the	radiology	department.	
This	database	included	patient	identifiers,	date	of	imaging	study,	size	of	pulmonary	
nodule	identified,	and	recommendations	for	nodule	follow-up.	This	was	a	clinical	
database	that	had	been	established	the	year	prior	as	part	of	a	quality	improvement	
project	to	improve	pulmonary	nodule	follow-up	at	BMC.	Initially,	all	information	used	in	
this	database	was	to	be	used	for	this	study.	However,	while	performing	random	chart	
review	on	500	patients	in	the	database	to	verify	data	integrity,	numerous	errors	were	
found	in	the	recording	of	nodule	size	and	follow-up	recommendations.	Consequently,	
the	only	data	used	from	this	database	were	patient	medical	record	numbers	that	
indicated	a	new	diagnosis	of	a	pulmonary	nodule	during	the	study	period	of	interest.		
We	used	this	information	to	assemble	a	cohort	of	patients	with	newly	diagnosed	
pulmonary	nodules.	
	
We	then	obtained	data	about	patient	characteristics,	imaging	study,	and	nodule	
characteristics	for	patients	in	our	cohort	from	the	BMC	Clinical	Data	Warehouse	(CDW).	
These	data	included	patient	demographics,	primary	language,	insurance	status,	smoking	
history,	education	level,	radiology	report	from	imaging	study	of	interest,	patient	
comorbidities	(based	on	ICD-9	codes),	zip	code,	and	subsequent	chest	CT	occurring	after	
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the	initial	pulmonary	nodule	diagnosis.	Patient	zip	code	was	used	to	estimate	median	
income	based	on	data	from	the	U.S.	Census	from	2011–2015.105	Pulmonary	nodule	size	
was	obtained	from	the	radiology	report	as	well	as	through	chart	review.	Patient	data	
were	verified	and	missing	data	were	supplemented	using	chart	review.		
	
Inclusion	and	Exclusion	Criteria	
All	adult	patients	who	were	diagnosed	with	a	new	pulmonary	nodule	between	2011	and	
2014	at	BMC	were	included	in	this	study.	As	a	level	1	trauma	center	and	tertiary	care	
center,	BMC	sees	a	wide	array	of	patients	who	receive	their	primary	medical	care	across	
the	country.	This	meant	there	was	a	chance	that	a	patient	found	to	have	a	pulmonary	
nodule	at	BMC	may	subsequently	have	their	follow-up	care	at	another	institution.	To	
assure	that	all	follow-up	data	for	patients	would	be	available,	I	included	only	patients	
who	had	an	office	visit	in	a	primary	care	clinic	(internal	medicine,	family	medicine,	or	
geriatrics)	or	in	pulmonary	clinic	at	BMC	in	the	year	prior	to	or	year	following	the	
diagnosis	of	their	pulmonary	nodule.		
	
Patients	were	excluded	from	the	study	if	their	pulmonary	nodule	was	greater	than	3cm,	
if	the	nodule	had	been	previously	detected	prior	to	the	study	period,	or	if	they	died	
prior	to	the	recommended	follow-up	period	based	on	the	2005	Fleischner	Society	
Guidelines.	Additionally,	patients	were	excluded	if	they	had	a	pulmonary	nodule	that	did	
not	require	follow-up.	Based	on	Fleischner	guidelines,	nonsmokers	with	a	nodule	of	
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4mm	or	less	in	diameter	do	not	require	follow-up	and	therefore	were	excluded.	Finally,	
patients	initially	included	who	were	found	to	not	actually	have	a	nodule	on	imaging	or	
who	had	a	nodule	with	no	size	reported	were	also	excluded.		
	
Primary	and	secondary	outcomes	
The	primary	outcome	of	this	study	was	the	proportion	of	patients	who	received	
pulmonary	nodule	evaluation	consistent	with	the	2005	Fleischner	Society	guidelines	
among	all	patients	in	the	cohort.	Evaluation	was	dichotomized	as	guideline	concordant	
(at	least	as	aggressive	as	recommended	by	the	guidelines)	or	guideline	non-concordant	
(under-evaluation)	based	on	comparison	of	the	expected	follow-up	time	period	and	the	
actual	follow-up	occurrence.	The	recommended	pulmonary	nodule	follow-up	dates	
were	determined	based	on	the	Fleischner	Society	guidelines56	using	patient	smoking	
history	and	nodule	size.	When	the	recommended	follow-up	consisted	of	a	date	range,	
the	longer	period	in	the	range	was	used	for	a	follow-up	period	(i.e.,	6	months	if	the	
follow-up	recommendation	was	3	to	6	months).	Follow-up	evaluation	consisted	of	either	
a	chest	CT,	PET	scan,	bronchoscopy,	or	biopsy	occurring	within	30	days	of	the	
recommended	period.	Due	to	the	nature	of	the	data,	it	was	not	possible	to	determine	if	
a	repeat	CT	scan	was	obtained	prior	to	the	recommended	date	for	a	different	clinical	
reason,	thereby	making	it	challenging	to	determine	if	patients	are	receiving	pulmonary	
nodule	follow-up	more	aggressive	than	recommend.	Additionally,	as	previously	stated,	
missing	the	opportunity	to	intervene	early	on	malignancy	is	typically	the	greatest	
		 25	
concern	of	patients,	clinicians,	and	healthcare	systems.98,100,104	Therefore,	a	follow-up	
study	occurring	prior	to	the	recommended	time	frame	was	still	considered	in	
concordance	with	the	guidelines	in	this	study.	The	main	secondary	outcome	in	this	study	
was	any	pulmonary	nodule	follow-up,	defined	as	a	patient	receiving	follow-up	
evaluation	at	any	time	during	the	study	period.		
	
	
Statistical	Analysis	
Guideline	concordance	was	calculated	by	measuring	the	proportion	of	patients	receiving	
follow-up	prior	to	30	days	beyond	guideline-recommended	time	period.	Chi-squared	
and	student	t-tests	were	used,	as	appropriate	to	evaluate	associations	between	patient	
characteristics	and	guideline	concordant	pulmonary	nodule	follow-up.	All	tests	for	
significance	were	two	tailed.	The	Kruskal-Wallis	test	was	used	to	compare	median	
income	between	groups.	Income	was	estimated	based	upon	zip	code	data	obtained	
from	United	States	Census	data.	Variables	believed	to	be	potential	confounders	(age,	
gender,	race/ethnicity,	insurance	status,	education	level,	smoking	history,	and	median	
income)	as	well	as	those	strongly	associated	with	guideline	concordant	follow-up	in	
binary	analysis	were	included	in	a	multivariable	logistic	regression	model,	with	the	
dichotomous	outcome	of	guideline	concordant	follow-up	(yes/no)	as	the	dependent	
variable.	Odds	ratios	were	calculated	and	reported	with	a	95%	confidence	interval.		
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In	secondary	analyses,	I	also	assessed	whether	patients	had	follow-up	for	a	newly	
diagnosed	pulmonary	nodule	at	any	point	during	the	study	period.	The	statistical	
approach	was	the	same	except	for	using	any	follow-up	as	the	dependent	dichotomized	
variable.	Additionally,	I	also	evaluated	patients	with	nodules	of	7mm	or	greater	using	
the	same	approach	to	determine	differences	in	patients	receiving	guideline	concordant	
follow-up	compared	with	delayed	or	no	follow-up	for	nodules	at	high	risk	of	being	
malignant.		
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RESULTS	
Of	3916	patients	diagnosed	with	a	pulmonary	nodule	between	2011	and	2014,	1152	
patients	were	evaluated	after	applying	the	inclusion	and	exclusion	criteria	(Figure	3).	
Included	patients	in	this	study	represented	the	overall	demographic	of	patients	who	
receive	their	care	at	BMC,	with	a	large	proportion	of	minorities,	large	number	of	
uninsured	and	Medicaid	patients,	and	low	education	level	(Table	1).		
	
	
Figure 3: Patients with a pulmonary nodule diagnosis during the study time period who 
were excluded and included from analyses. 
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Table	1:	Patient	characteristics	of	all	included	patients.	
 
Patient	characteristic	 All	included	participants	
(n=1152)	
Age	[mean	(SD)]	 60.5	(13.4)	
Male	sex	 48.0%	
Ethnicity	 	
				White	Non-Hispanic	 36.9%	
				Black	Non-Hispanic	 45.3%	
				Hispanic/Latino	 11.4%	
				Other	 6.4%	
English	as	primary	language	 78.4%	
Insurance	 	
				Medicare	 38.0%	
				Medicaid	 32.6%	
				Private	 21.4%	
				Uninsured	 8.0%	
Current	or	former	smoker	 73.4%	
Marital	Status	 	
				Single	 40.6%	
				Married	 33.7%	
				Other	 25.7%	
Education	level	 	
				Less	than	high	school	 14.9%	
				High	School	 67.7%	
				College	or	advanced	degree	 18.2%	
BMI	[mean	(SD)]	 29.0	kg/m2	(8.4	kg/m2)	
Income	[median	(IQR)]	 $52,122	($25,785)	
	
Of	the	1152	patients	evaluated	in	this	study,	613	(53.2%)	received	follow-up	within	the	
time	frame	recommended	by	Fleischner	Society	guidelines.	Of	the	539	patients	receiving	
guideline	non-concordant	follow-up,	307	(57.0%)	had	no	follow-up	evaluation	at	any	
point	during	the	study	period.	In	binary	analysis,	increasing	nodule	size	(p=0.05),	white	
non-Hispanic	race/ethnicity	(p=0.04),	and	a	concurrent	diagnosis	of	COPD	were	
significantly	associated	with	having	guideline	concordant	follow-up	(Table	2).	While	
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insurance	status	did	not	reach	statistical	significance	in	this	analysis,	point	estimates	
suggest	a	higher	percentage	of	uninsured	patients	in	the	guideline	non-concordant	
group	(9.8%)	compared	to	the	guideline	concordant	group	(6.3%).			
	
Table	2:	Comparison	in	characteristics	of	patients	receiving	guideline	concordant	
pulmonary	nodule	follow-up	and	patients	receiving	non-concordant	follow-up.	
Differences	found	to	be	statistically	significant	at	a	significance	value	of	0.05	are	
highlighted	in	bold.	
	
Patient	characteristic	 Guideline	
concordant	(n=613)	
Guideline	non-
concordant	(n=539)	
p-value	
Age	at	scan	[mean	(SD)]	 60.6	(12.3)	 60.4	(14.5)	 0.77	
Male	gender	 296	(48.3%)	 257	(47.7%)	 0.84	
Ethnicity	 	 	 0.04	
				Black	non-Hispanic	 260	(43.1%)	 252	(47.7%)	 	
				White	non-Hispanic	 242	(40.1%)	 175	(33.1%)	 	
				Hispanic/Latino	 59	(9.8%)	 70	(13.3%)	 	
				Other	 42	(7.0%)	 31	(5.9%)	 	
English	as	primary	language	 488	(79.7%)	 413	(76.8%)	 0.22	
Insurance	 	 	 0.13	
				Medicare	 245	(40.0%)	 193	(35.8%)	 	
				Medicaid	 198	(32.3%)	 177	(32.9%)	 	
				Private	 131	(21.4%)	 116	(21.5%)	 	
				Uninsured	 39	(6.3%)	 53	(9.8%)	 	
Current	or	former	smoker	 450	(73.4%)	 396	(73.5%)	 0.98	
Marital	Status	 	 	 0.21	
				Single	 235	(38.3%)	 233	(43.2%)	 	
				Married		 211	(34.4%)	 177	(32.8%)	 	
				Other	 167	(27.2%)	 129	(23.9%)	 	
Education	level	 	 	 0.24	
				8th	grade	or	less	 85	(14.5%)	 78	(15.4%)	 	
				High	School	 406	(69.1%)	 328	(64.6%)	 	
				College/professional	degree	 97	(16.5%)	 102	(20.1%)	 	
BMI	[mean	(SD)]	 28.7	kg/m2	
(7.1	kg/m2)	
29.4	kg/m2	
(9.8	kg/m2)	
0.20	
Income	[median	(IQR)]	 $52,122	 $54,883	 0.69	
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Nodule	size	 	 	 0.05	
				<=	4mm	 192	(31.3%)	 208	(38.6%)	 	
				5–6mm	 191	(31.2%)	 164	(30.4%)	 	
				7–8mm	 101	(16.5%)	 71	(13.2%)	 	
				>8	 129	(21%)	 96	(17.8%)	 	
History	of	COPD	 173	(28.2%)	 99	(18.4%)	 <0.01	
History	of	diabetes	 175	(28.6%)	 136	(25.2%)	 0.21	
History	of	chronic	renal	
disease	
67	(10.9%)	 53	(9.8%)	 0.54	
		
	
In	multivariable	logistic	regression	analysis	(Table	3),	Hispanic	patients	were	found	to	
have	a	significantly	lower	rate	of	guideline	concordant	follow-up	compared	to	white	
non-Hispanics	(OR	0.59,	95%	CI	0.36-0.97).	Additionally,	uninsured	patients	were	less	
likely	to	have	guideline	concordant	follow-up	compared	to	patients	with	Medicare.	
Similar	to	the	pattern	seen	in	binary	analysis,	there	is	an	increasing	likelihood	of	
guideline	concordant	follow-up	with	increasing	nodule	size.	Finally,	patients	with	COPD	
were	found	to	have	twice	the	odds	of	having	guideline	concordant	follow-up	compared	
to	those	without	COPD	(OR	2.00,	95%	CI	1.45–2.75).	
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Table	3:	Multivariable	logistic	regression	analysis	comparing	patients	with	guideline	
concordant	follow-up	to	guideline	non-concordant	follow-up.	Characteristics	reaching	
statistical	significance	highlighted	in	bold.	
	
	
	
	
	
	
	
	
	
	
	
	
Similar	patterns	were	observed	when	evaluating	which	patients	had	any	follow-up	at	
any	time	during	the	study	period	(Figure	4).	With	increasing	nodule	size,	there	was	an	
increasing	rate	of	not	only	guideline	concordant	follow-up,	but	overall	follow-up	as	well	
(Figure	4a).	While	only	15%	of	patients	with	a	nodule	greater	than	8mm	had	no	follow-
up	at	any	time	during	the	study	period,	nearly	35%	of	patients	with	a	nodule	4mm	or	
less	had	no	follow-up.	When	categorizing	patients	by	race/ethnicity	(Figure	4b),	
Hispanic/Latino	patients	had	not	only	less	guideline	concordant	follow-up	compared	to	
whites	(45.7%	vs.	58.0%,	p=0.01),	but	also	higher	rates	of	having	no	follow-up	(33.3%	vs.	
21.6%,	p<0.01).	Patient	insurance	status	also	was	associated	having	no	follow-up	(33.3%		
Patient	characteristic	 Odds	ratio	(95%	CI)	 p-value	
Race/Ethnicity	 		
	
				White	Non-Hispanic	 Ref	
	
				Black	Non-Hispanic	 0.80	(0.59–1.08)	 0.14	
				Hispanic	 0.59	(0.36–0.97)	 0.04	
				Other	 1.12	(0.61–2.07)	 0.72	
Insurance	
	 	
				Medicare	 Ref	
	
				Medicaid	 0.87	(0.62–1.20)	 0.39	
				Commercial/Private	 0.88	(0.62–1.24)	 0.46	
				Uninsured	 0.56	(0.33–0.96)	 0.04	
Nodule	Size	
	 	
				4mm	or	less	 Ref	
	
				5	to	6mm	 1.36	(0.98–1.88)	 0.07	
				7	to	8mm	 1.58	(1.06–2.37)	 0.03	
				Greater	than	8mm	 1.63	(1.12–2.37)	 0.01	
History	of	COPD	 2.00	(1.45–2.75)	 <0.01	
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Figure	4:	Rates	of	guideline	concordant	follow-up,	delayed	follow-up,	and	no	follow-up	
based	on	(a)	nodule	size,	(b)	patient	race/ethnicity,	and	(c)	patient	insurance	status.	
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(c)		
	
vs.	21.6%,	p<0.01).		Patient	insurance	status	also	was	associated	with	both	guideline	
concordant	follow-up	and	any	follow-up	(Figure	4c).	Uninsured	patients	had	significantly	
less	guideline	concordant	follow-up	compared	to	Medicare	patients	(42.4%	vs.	55.9%,	
p=0.02)	as	well	as	higher	rates	of	having	no	follow-up	during	the	study	period	(42.4%	vs.	
21.2%,	p<0.01).	
	
In	the	binary	analysis	of	patients	with	larger	nodules	(Table	4),	measuring	7mm	or	
greater,	patients	with	a	concurrent	diagnosis	of	COPD	were	more	likely	to	have	
guideline	concordant	follow-up	than	those	without	COPD	(p<0.01).	In	multivariate	
analysis	(Table	5),	Hispanic	patients	were	again	found	to	have	a	significantly	lower	
likelihood	of	having	guideline	concordant	follow-up	compared	to	white	non-Hispanics		
0%10%
20%30%
40%50%
60%70%
80%90%
100%
Medicare Medicaid Private/Commercial UninsuredInsuranceGuideline	concordant Delayed	Follow-up No	follow-up
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Patient	characteristic	 Guideline	concordant	
(n=230)	
Guideline	non-
concordant	(n=167)	
p-value	
Age	at	scan	[mean	(SD)]	 61.6	(13.4)	 62.0	(16.1)	 0.82	
Male	gender	 106	(46.1%)	 66	(39.5%)	 0.19	
Ethnicity	 	 	 0.12	
				Black	non-Hispanic	 90	(39.8%)	 70	(43.2%)	 	
				White	non-Hispanic	 97	(42.9%)	 59	(36.4%)	 	
				Hispanic/Latino	 18	(8.0%)	 23	(14.2%)	 	
				Other	 21	(9.3%)	 10	(6.2%)	 	
English	as	primary	language	 169	(73.5%)	 119	(71.7%)	 0.69	
Insurance	 	 	 0.60	
				Medicare	 91	(39.6%)	 58	(34.9%)	 	
				Medicaid	 77	(33.5%)	 68	(34.9%)	 	
				Private	 46	(20.0%)	 33	(19.9%)	 	
				Uninsured	 16	(7.0%)	 17	(10.2%)	 	
Current	or	former	smoker	 143	(62.2%)	 96	(57.5%)	 0.35	
Marital	Status	 	 	 0.94	
				Single	 83	(36.1%)	 63	(37.7%)	 	
				Married		 83	(36.1%)	 59	(35.3%)	 	
				Other	 64	(27.8%)	 45	(27.0%)	 	
Education	 	 	 0.22	
				8th	grade	or	less	 141(18.7%)	 28	(18.4%)	 	
				High	School	 143	(65.3%)	 89	(58.6%)	 	
				College/professional	degree	 35	(16.0%)	 35	(23.0%)	 	
BMI	[mean	(SD)]	 28.4	(7.0)	 28.4	(7.0)	 0.95	
Income	[median	(IQR)]	 $60,071	($28,056)	 $55,795	($29,510)	 0.07	
History	of	COPD	 68	(29.6%)	 23	(13.8%)	 <0.01	
History	of	diabetes	 64	(27.8%)	 37	(22.2%)	 0.20	
History	of	renal	disease	 27	(11.7%)	 13	(7.8%)	 0.20	
	
	 	
Table	4:	Comparison	in	characteristics	of	patients	with	nodules	7mm	or	greater	
receiving	guideline	concordant	and	non-concordant	pulmonary	nodule	follow-up.	
Differences	found	to	be	statistically	significant	at	a	significance	value	of	0.05	are	
highlighted	in	bold.	
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(OR	0.42,	CI	0.18–0.99)	and	patients	with	COPD	had	significantly	higher	odds	of	having	
guideline	concordant	care	compared	to	those	without	(OR	2.71,	CI	1.47–4.99).	
Uninsured	patients	had	0.41	times	the	odds	of	having	guideline	concordant	follow-up	
compared	to	Medicare	patients,	although	this	did	not	reach	statistical	significance	with	
a	p-value	of	0.09.	Similar	patterns	were	again	noted	among	patients	with	nodules	
measuring	7mm	or	greater	who	had	any	follow-up	during	the	study	period	(Figure	5).	
	
	
	
	
	
	
	
	
	 	
	Patient	characteristic	 Odds	ratio	(95%	CI)	 p-value	
Race/Ethnicity	 		 	
				White	Non-Hispanic	 Ref	 	
				Black	Non-Hispanic	 0.86	(0.49–1.50)	 0.59	
				Hispanic	 0.42	(0.18–0.99)	 0.05	
				Other	 1.50	(0.50–4.54)	 0.47	
Insurance	 	 	
				Medicare	 Ref	 	
				Medicaid	 0.71	(0.39–1.31)	 0.27	
				Commercial/Private	 0.90	(0.47–1.71)	 0.74	
				Uninsured	 0.41	(0.15–1.16)	 0.09	
COPD	 2.71	(1.47–4.99)	 <0.01	
Table	5:	Multivariable	logistic	regression	analysis	comparing	patients	with	guideline	
concordant	follow-up	to	guideline	non-concordant	follow-up	for	nodules	7mm	or	greater.	
Characteristics	reaching	statistical	significance	highlighted	in	bold.	
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Figure	5:	Rates	of	guideline	concordant	follow-up,	delayed	follow-up,	and	no	follow-up	
for	patients	with	nodules	of	7mm	or	greater	based	on	(a)	patient	race/ethnicity,	and	(b)	
patient	insurance	status.	
 
a)	
	
b)	
0%10%
20%30%
40%50%
60%70%
80%90%
100%
Medicare Medicaid Private/Commercial UninsuredInsuranceGuideline	concordant Delayed	Follow-up No	follow-up
0%10%
20%30%
40%50%
60%70%
80%90%
100%
White	Non-Hispanic Black	Non-Hispanic Hispanic/Latino OtherRace/ethnicityGuideline	concordant Delayed	Follow-up No	follow-up
		 37	
DISCUSSION	
This	study	explored	the	proportion	of	patients	with	newly	detected	incidental	
pulmonary	nodules	who	received	appropriate	pulmonary	nodule	follow-up	at	BMC	
based	upon	2005	Fleischner	Society	guidelines.	While	overall	there	was	a	low	proportion	
of	guideline-concordant	follow-up	(53.2%),	this	is	consistent	with	prior	studies	that	have	
assessed	pulmonary	nodule	guideline	implementation.59–61	In	my	study,	the	rate	of	
concordance	only	included	follow-up	at	least	as	aggressive	as	the	guidelines	recommend.	
The	actual	concordance	rate	likely	would	be	significantly	lower	if	taking	into	
consideration	imaging	studies	occurring	earlier	than	recommended,	given	over-
evaluation	may	occur	in	up	to	28%	of	cases.60,106	Early	evaluation	was	not	included	in	
this	study	given	the	inability	to	determine	whether	a	subsequent	CT	scan	was	obtained	
for	a	different	clinical	reason.	In	these	cases,	the	study	may	have	been	intended	to	
evaluate	a	different	disease	(such	as	a	pulmonary	embolism	or	pneumonia),	but	the	
nodule	could	also	be	reassessed	at	this	earlier	interval.	Additionally,	any	follow-up	chest	
CT	was	considered	a	potential	follow-up	study	without	knowledge	of	the	clinical	
indication	for	the	study.	It	is	likely	that	a	significant	number	of	follow-up	studies	were	
obtained	for	a	different	clinical	purpose	and	that	“nodule	follow-up”	occurred	merely	
incidentally.	For	these	reasons,	it	would	seem	the	guideline	concordant	follow-up	rate	
obtained	in	this	study	likely	represents	the	best-case	scenario	and	that	the	actual	rate	of	
guideline	concordance	is	considerably	less.		
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While	confirming	the	low	penetration	of	guideline-recommended	pulmonary	nodule	
care	into	clinical	practice,	this	study	also	identified	potential	barriers	to	guideline	
concordant	pulmonary	nodule	care.	Smaller	nodules	had	higher	rates	of	delayed	and	
absent	follow-up,	with	higher	rates	of	guideline	concordance	as	nodule	size	increased.	
This	may	be	due,	in	part,	to	clinicians	and	patients	appropriately	having	greater	concern	
for	larger	nodules	and	thus	having	closer	and	more	reliable	follow-up.	In	other	words,	
this	pattern	may	simply	represent	greater	concern,	as	opposed	to	a	greater	likelihood	of	
being	in	accordance	with	guidelines.	Prior	studies	have	found	mixed	results	for	how	
nodule	size	is	associated	with	guideline-recommended	follow-up.	While	one	study	
found	no	difference	in	guideline	adherence	based	on	nodule	size,61	another	found	
adherence	was	highest	for	nodules	measuring	4–6mm	and	decreased	as	nodule	size	
increased	or	decreased.107	My	study	findings	differ	from	these	prior	studies,	with	nodule	
size	being	having	a	strong	and	graded	association	with	guideline	concordance.	In	cases	
where	the	risks	of	malignancy	are	highest,	clinicians	and	patients	are	potentially	more	
likely	to	follow	recommendations	given	increased	concern	about	a	potentially	life-
threatening	diagnosis.	Nonetheless,	even	for	nodules	measuring	7mm	or	greater,	overall	
guideline	concordance	increased	to	only	57.9%.	While	larger	nodules	did	have	a	greater	
rate	of	guideline	concordant	follow-up,	there	remained	a	significant	number	of	patients	
receiving	delayed	or	absent	follow-up	even	for	these	higher	risk	nodules.	
	
This	study	found	Hispanic	patients	to	have	0.59	times	the	odds	of	having	guideline	
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concordant	follow-up	compared	to	white	non-Hispanic	patients.	What	was	most	
interesting	about	this	finding	was	that	the	association	was	significant	even	when	
controlling	for	language,	education,	and	income.	There	appears	to	be	some	barrier	
unique	to	Hispanics,	given	there	was	no	similar	finding	in	other	minority	groups.	With	
language	and	socioeconomic	factors	not	playing	a	significant	role,	one	must	consider	
whether	there	are	inherent	cultural	issues	that	impede	Hispanic	patients	from	receiving	
guideline-concordant	care.92,93	This	finding	is	not	unique	to	pulmonary	nodule	
management,	as	Hispanic	patients	have	been	found	to	have	lower	rates	of	guideline	
concordant	care	in	many	other	conditions:	liver	disease,108,109	breast	cancer	diagnosis	
and	treatment,110,111	and	preventive	care112	among	many	others.	In	one	attempt	to	
identify	an	explanation	for	these	disparities	in	care,	Colen	et	al.	evaluated	the	role	of	
acute	and	chronic	discrimination	in	the	health	gap	between	different	races	and	
ethnicities.113	Interestingly,	while	this	study	found	exposure	to	unfair	treatment	
explained	a	significant	of	disparity	in	the	care	of	black	patients,	there	was	no	such	
association	with	disparity	in	care	for	Hispanics.113	While	the	cause	for	disparities	among	
Hispanics	is	multifactorial,	several	qualitative	studies	in	other	medical	conditions	shed	
potential	light	on	why	Hispanics	often	receive	sub-optimal	care.114–116	While	these	
studies	involve	different	medical	conditions,	there	are	some	common	themes	that	arise	
as	potential	barriers	for	Hispanic	patients.	For	instance,	patients	across	these	studies	
report	low	health	literacy,	with	difficulty	understanding	how	and	why	medical	tests	and	
procedures	need	to	be	performed.114,115	Additionally,	patients	are	concerned	about	how	
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a	medical	diagnosis	might	affect	not	only	their	own	well-being,	but	the	well-being	of	
their	family.116	Finally,	there	are	several	comments	that	reflect	a	lack	of	perceived	social	
support	among	patients.114–116	Any	or	all	of	these	factors	may	potentially	explain	why	
Hispanics	in	my	study	received	less	guideline	concordant	care	compared	to	non-
Hispanics.	
	
There	were	also	significantly	lower	rates	of	guideline	concordance	in	patients	who	were	
uninsured.	This	may	be	primarily	due	to	lack	of	adequate	healthcare	access	and	inability	
of	patients	to	pay	for	follow-up	tests	out-of-pocket.	Several	studies	have	documented	
lower	rates	of	healthcare	utilization,	particularly	in	preventive	care,	for	patients	that	are	
uninsured.117–119	There	are	other	potential	contributing	factors	for	why	uninsured	
patients	may	receive	suboptimal	care.	Uninsured	patients	often	have	low	health	literacy	
and	increased	difficulty	with	navigating	the	healthcare	system.120	Additionally,	even	
when	uninsured	patients	have	healthcare	access,	this	access	may	be	inadequate	for	all	
their	health	needs.	Given	that	uninsured	patients	have	higher	prevalence	of	
comorbidities,121	there	may	be	need	to	prioritize	health	conditions	due	to	limited	time	
or	financial	resources.	For	instance,	follow-up	of	a	pulmonary	nodule	may	be	delayed	or	
even	ignored	in	order	to	first	manage	poorly	controlled	diabetes,	congestive	heart	
failure,	or	significant	mental	illness.	In	such	cases,	it	may	even	be	justifiable	to	not	
follow	pulmonary	nodule	guidelines	and	individualize	the	follow-up	plan	based	on	that	
specific	patient’s	needs.		
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The	strongest	association	with	guideline	concordant	follow-up	in	this	study	was	a	co-
diagnosis	of	COPD.	The	diagnosis	of	a	pulmonary	nodule	in	a	patient	with	COPD	often	
presents	an	interesting	conundrum.	On	the	one	hand,	patients	with	COPD	are	at	higher	
risk	of	having	lung	cancer,	suggesting	an	identified	nodule	has	greater	likelihood	of	
being	malignant	than	in	patients	without	COPD.122,123	On	the	other	hand,	patients	with	
COPD	have	increased	risk	of	complications	related	to	the	diagnostic	evaluation	of	
pulmonary	nodules	or	potentially	curative	lung	resection.70,71,124	My	study	found	patients	
with	COPD	to	have	twice	the	odds	of	having	guideline	concordant	pulmonary	nodule	
follow-up	compared	to	those	without	COPD.	One	potential	explanation	would	be	that	
patients	and	their	clinicians	in	this	study	were	more	concerned	with	the	risks	of	
malignancy	and	less	about	potential	complications,	given	the	most	common	follow-up	in	
this	study	was	non-invasive	CT	imaging.	Another	potential	explanation	is	that	patients	
with	COPD	have	closer	follow-up	than	those	without	COPD,	thereby	having	more	
exposure	to	the	healthcare	system	and	more	opportunity	for	follow-up.	However,	
arguing	against	this	is	the	fact	that	neither	diabetes	nor	chronic	kidney	disease	(two	
chronic	conditions	that	require	frequent	follow-up)	were	associated	with	guideline	
concordant	care.	A	final,	and	perhaps	most	likely,	explanation	for	this	association	is	the	
role	of	pulmonary	specialists	in	the	care	of	COPD	patients.	COPD	patients	are	more	likely	
to	have	a	pulmonologist	following	their	respiratory	disease	who	may	concurrently	also	
follow	their	pulmonary	nodule.	It	is	possible	that	having	a	pulmonary	specialist	
managing	pulmonary	nodule	follow-up	was	an	unmeasured	confounder	that	could	be	
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linked	to	better	guideline	concordance.	This	may	be	due	to	better	familiarity	with	
pulmonary	nodule	guidelines	and	more	experience	with	the	intricacies	of	nodule	
management.125	Additionally,	pulmonologists	are	more	likely	than	other	clinicians	to	
refer	directly	to	the	guidelines	as	opposed	to	relying	on	recommendations	given	by	
radiologists	in	the	imaging	report.98	However,	several	prior	studies	have	documented	
that	even	pulmonary	specialists	often	do	not	follow	pulmonary	nodule	guidelines	
perhaps	due	to	low	faith	in	the	quality	of	evidence	upon	which	they	are	based.59,126	
Given	it	could	not	be	determined	from	the	available	data	which	patients	had	a	
pulmonologist	and	which	did	not,	additional	data	and	analysis	is	needed	to	better	
investigate	this	association.	
	
While	this	study	identified	several	patient	characteristics	associated	with	delayed	or	
absent	pulmonary	nodule	follow-up,	there	remain	multiple	other	factors	impeding	
implementation	of	guideline-recommended	pulmonary	nodule	practices.	At	the	onset	of	
this	study,	the	initial	plan	was	to	utilize	a	radiology	database	tracking	all	new	diagnoses	
of	pulmonary	nodules.	This	was	a	clinical	database	that	was	maintained	as	part	of	a	
quality	improvement	initiative	at	BMC.	However,	close	analysis	of	the	database	found	it	
unusable	for	this	study	given	frequent	errors	in	the	recording	of	nodule	size	or	in	the	
diagnosis	of	a	pulmonary	nodule	itself.	In	several	cases,	nodule	size	was	recorded	up	to	
10–15mm	different	from	its	actual	measurement.	This	clinical	database	had	been	used	
to	track	pulmonary	nodules	and	to	flag	clinicians	ordering	the	initial	study	about	the	
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need	for	follow-up.	These	numerous	errors	could	increase	the	risk	of	both	under-	and	
over-evaluation	of	pulmonary	nodules	by	alerting	physicians	to	a	nodule	of	the	wrong	
size	and	with	an	inaccurate	recommendation	for	follow-up.	In	these	cases,	even	if	all	
other	factors	were	optimized	and	both	patient	and	clinician	sought	to	adhere	to	
guideline-recommended	follow-up,	patients	would	still	not	be	receiving	the	
recommended	follow-up	evaluation.	What	is	perhaps	most	concerning	is	that	this	
occurred	in	a	dedicated	quality	improvement	project	at	a	major	academic	safety	net	
hospital.	If	nodule	evaluation	cannot	be	optimized	in	this	setting	with	minimal	
disparities	in	healthcare	delivery,	one	would	expect	other	institutions	that	do	not	have	
the	same	pulmonary	nodule	expertise	or	focus	on	at-risk	populations	would	have	even	
more	challenges	and	worse	outcomes.		
	
The	database	errors	as	well	as	patient	characteristics	associated	with	guideline	non-
concordance	exemplify	the	complexities	involved	in	patients	receiving	the	
recommended	pulmonary	nodule	follow-up.	The	interrelationships	between	patient	and	
clinician,	patient	and	healthcare	system,	and	clinician	and	healthcare	system	as	outlined	
in	my	conceptual	model	are	all	critical	to	performing	guideline	recommended	evaluation	
in	practice.	An	obstacle	in	any	of	these	relationships	(exemplified	by	the	database	entry	
errors	identified	in	my	study)	can	fracture	the	path	towards	guideline	concordant	care.	
So	how	do	we	optimize	these	paths	and	improve	pulmonary	nodule	guideline	
concordance	and	outcomes?	My	study	highlights	several	areas	in	nodule	management	
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that	could	be	potential	targets	for	intervention.	First,	it	is	essential	to	recognize	the	
need	to	dedicate	resources	to	pulmonary	nodule	follow-up	and	to	develop	a	
streamlined	process	for	nodule	evaluation.	The	database	issues	found	during	this	study	
were	not	unique	to	this	institution.	In	fact,	many	institutions	lack	the	resources	and	
infrastructure	needed	to	facilitate	pulmonary	nodule	evaluation	and	prevent	loss	of	
follow-up.97	Complicating	this	further	is	the	role	of	several	medical	disciplines	in	the	
pulmonary	nodule	follow-up	process,	as	this	may	involve	the	ordering	provider	(any	
specialty),	radiology,	surgeons,	pulmonologists,	primary	care	physicians,	and	oncologists.	
While	results	of	dedicated	nodule	clinics	have	been	somewhat	mixed,59	there	have	been	
successful	implementation	of	similar	clinics	in	other	specialties,	such	as	thyroid	
nodules.127	There	are	multiple	benefits	to	these	specialty	clinics,	including	a	clear	
identification	of	clinician	ownership	of	pulmonary	nodule	management,	expertise	in	
navigating	nuances	of	follow-up,	and	pooling	of	resources	to	assure	the	necessary	
infrastructure	and	processes	are	in	place.	However,	this	type	of	specialization	is	not	
always	possible,	particularly	in	more	remote	settings	where	resources	and	healthcare	
access	are	more	limited.	
	
Another	area	for	investigation	is	in	regards	to	the	guideline	recommendations	
themselves.	Nearly	half	of	patients	with	a	nodule	measuring	6mm	or	less	in	this	study	
received	the	appropriate	follow-up	according	to	the	2005	Fleischner	Society	guidelines.	
However,	it	is	unclear	based	upon	the	evidence	if	and	when	nodules	of	this	size	even	
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need	to	be	followed.	Perhaps	the	guideline	concordant	follow-up	rate	for	nodules	this	
small	is	so	low	due	to	clinicians’	attitude	towards	the	low	quality	of	evidence	for	this	
recommendation.	In	a	recent	study,	nearly	90%	of	clinicians	reported	willingness	to	
enroll	patients	in	a	clinical	trial	comparing	current	guideline	recommendations	for	low	
risk	nodules	to	less	frequent	surveillance	strategies.126	In	fact,	the	Fleischner	Society	
recently	released	updated	guidelines	recommending	no	follow-up	for	low-risk	patients	
with	nodules	up	to	6mm	and	optional	follow-up	for	high-risk	patients	with	nodules	up	to	
6mm.128	So	while	half	of	patients	with	nodules	of	this	size	in	my	study	received	delayed	
or	absent	follow-up	according	to	the	2005	guidelines,	it	is	unclear	what,	if	any,	impact	
this	may	have	on	their	overall	outcomes.	Similarly,	there	is	discrepancy	amongst	
guidelines	themselves	about	how	and	when	nodules	should	be	evaluated.	The	American	
College	of	Chest	Physicians,	British	Thoracic	Society,	and	Fleischner	Guidelines,	for	
instance,	all	have	similar	but	different	recommendations	and	algorithms	for	follow-
up.19,56,64,128	With	guidelines	themselves	not	in	agreement,	it	is	challenging	for	clinicians	
and	patients	to	determine	the	best	approach	and	time	period	for	follow-up.	In	order	to	
clarify	guidelines	and	better	delineate	which	patients	benefit	from	close	follow-up	and	
for	which	less	aggressive	follow-up	is	preferred,	further	studies	are	needed	to	assess	
patient-oriented	outcomes	at	various	nodule	follow-up	intervals.	In	fact,	the	Patient-
Centered	Outcomes	Research	Institute	recently	funded	a	multi-million	dollar,	multi-
center	trial	investigating	various	intervals	of	follow-up	is	currently	ongoing,	with	BMC	
being	a	participating	state.129	
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A	final	area	of	potential	intervention	is	at	the	patient	level.	In	this	study,	while	Hispanic	
patients	and	uninsured	patients	had	lower	rates	of	guideline	concordant	follow-up,	non-
Hispanics	and	insured	patients	still	had	overall	low	rates	of	guideline	concordant	follow-
up.	Improving	the	disparity	in	care	is	not	sufficient	on	its	own	to	optimize	overall	patient	
outcomes	in	pulmonary	nodule	management.	However,	there	are	potential	lessons	that	
can	be	learned	from	these	groups	with	lower	rates	of	follow-up.	Uninsured	and	Hispanic	
patients	both	have	been	found	to	have	low	rates	of	health	literacy	and	difficulty	
interacting	with	the	healthcare	system.114,120	With	pulmonary	nodules,	however,	these	
traits	are	not	necessarily	unique	to	these	groups.	Prior	studies	have	found	patients	have	
difficulty	understanding	the	diagnosis	of	a	pulmonary	nodule	in	part	due	to	poor	
communication	from	healthcare	providers.72,73,104	Pulmonary	nodule	guidelines	from	the	
American	College	of	Chest	Physicians	recommend	shared	decision-making	in	order	for	
patient	preferences	to	play	a	critical	role	in	the	decision-making	process.64,130	While	the	
complexity	and	uncertainty	surrounding	pulmonary	nodule	evaluation	can	make	it	
challenging	to	communicate	with	patients	and	engage	them	in	the	decision-making	
process,	these	are	the	ideal	moments	for	implementing	shared	decision-making	
discussions.131	Multiple	studies	have	found	that	including	patients	in	the	decision-
making	process	can	improve	their	overall	satisfaction	with	their	care	as	well	as	
adherence	to	medical	recommendations.71–73,132	Better	engagement	of	patients	in	
discussing	the	diagnosis	of	a	pulmonary	nodule	and	utilization	of	shared	decision-
making	to	determine	the	optimal	plan	for	follow-up	evaluation	may	be	one	potential	
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way	to	improve	patient	adherence	to	recommendations	and	rates	of	guideline	
concordant	follow-up.	
	
This	study	has	limitations.	Any	CT	imaging	study	occurring	after	the	initial	pulmonary	
nodule	diagnosis	was	considered	a	potential	follow-up	study,	but	the	reason	for	
obtaining	the	study	could	not	be	ascertained.	As	such,	some	follow-up	studies	may	have	
not	been	actually	intended	to	be	follow-up.	This	would	potentially	make	the	guideline	
concordant	follow-up	rates	lower	than	that	found	in	this	study.	While	steps	were	taken	
to	ensure	patients	in	this	study	had	their	primary	medical	care	at	BMC,	it	is	possible	that	
some	patients	may	have	had	follow-up	imaging	or	evaluation	at	another	institution	after	
the	initial	diagnosis	that	we	could	not	capture.	However,	by	including	only	patients	with	
a	primary	care	or	pulmonary	clinic	visit	within	a	year	before	or	after	diagnosis,	the	
frequency	of	patients	having	follow-up	at	another	institution	was	likely	low.	Finally,	
while	this	study	evaluated	patient	characteristics	associated	with	guideline	concordant	
follow-up,	reasons	for	delayed	or	absent	follow-up	could	not	be	obtained	from	the	
dataset.	Patient	preference	or	competing	clinical	conditions	with	higher	acuity	could	be	
potentially	appropriate	reasons	for	not	following	guideline	recommendations,	neither	of	
which	could	be	captured	in	this	study.		
	
While	this	study	found	some	potential	sources	for	why	pulmonary	nodule	guidelines	are	
infrequently	followed	in	practice,	further	research	is	needed	to	better	understand	
		 48	
barriers	and	how	they	are	best	overcome.	Additional	data	collection	and	analysis	is	
needed	to	further	explore	the	association	of	COPD	diagnosis	with	guideline	concordance,	
with	particular	attention	to	how	having	a	pulmonary	specialist	influences	follow-up	
rates.	Additional	analysis	would	also	aim	to	assess	whether	amount	of	healthcare	
utilization	is	associated	with	nodule	follow-up,	evaluating	how	number	of	clinic	visits	
within	the	study	period	may	be	associated	with	guideline	concordance.	Finally,	
implementation	studies	are	needed	to	explore	strategies	for	improving	workflow	and	
streamlining	the	process	of	identifying	nodules	in	higher	risk	patients,	communicating	
the	need	for	follow-up	to	patient	and	clinician,	scheduling	the	recommended	follow-up,	
and	ensuring	follow-up	is	completed	in	a	timely	manner.	These	initial	next	steps	will	
further	the	understanding	of	how	pulmonary	nodule	guideline	concordance	can	be	
improved	to	optimize	follow-up	and	overall	patient	outcomes.	
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CONCLUSION	
Overall,	the	rate	of	guideline	concordant	pulmonary	nodule	follow-up	was	found	to	be	
low.	Poor	healthcare	access	(uninsured)	and	cultural	factors	(Hispanics)	were	significant	
contributors	to	delayed	pulmonary	nodule	follow-up.	Additionally,	patients	at	higher	
risk	of	malignancy	(larger	nodules,	co-diagnosis	of	COPD),	had	higher	likelihood	of	
guideline	concordant	follow-up.	While	these	patient	characteristics	provide	some	
explanation	for	low	rates	of	follow-up,	additional	factors	at	the	patient,	clinician,	and	
healthcare	system	level	also	likely	contribute	to	the	difficulty	with	implementing	
guidelines	into	clinical	practice.	Future	work	is	needed	to	assess	how	the	complex	
patient-clinician,	patient-healthcare	system,	and	clinician-healthcare	system	dynamics	
may	influence	timely	pulmonary	nodule	evaluation.	
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